Volume 16, Issue 9 (December 2022)
Qom Univ Med Sci J 2022, 16(9): 744-755 |
Back to browse issues page
Ethics code: (IR.MUQ.REC.1399.176)
Clinical trials code: IRCT20201128049508N1
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Tabaraii R, Asghari A, jafari L, Vahedian M, Bagherzadeh M, Vafaee Manesh J. Effectiveness of Atorvastatin in Reducing Inflammatory Markers and Hospitalization Period in Adults With COVID-19: A Randomized Clinical Trial. Qom Univ Med Sci J 2022; 16 (9) :744-755
URL: http://journal.muq.ac.ir/article-1-3575-en.html
URL: http://journal.muq.ac.ir/article-1-3575-en.html
Reihane Tabaraii1 
, Akram Asghari1 , Leila Jafari * 2, Mostafa Vahedian3 , Mohammad Bagherzadeh1 , Jamshid Vafaee Manesh1
, Akram Asghari1 , Leila Jafari * 2, Mostafa Vahedian3 , Mohammad Bagherzadeh1 , Jamshid Vafaee Manesh1
1- Department of Internal, Faculty of Medicine, Clinical Research Development Center Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran.
2- Department of Internal, Faculty of Medicine, Clinical Research Development Center Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran. ,jafari.leila1@yahoo.com
3- Department of Statistics, Faculty of Medicine, Clinical Research Development Center Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran.
2- Department of Internal, Faculty of Medicine, Clinical Research Development Center Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran. ,
3- Department of Statistics, Faculty of Medicine, Clinical Research Development Center Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran.
Abstract: (1105 Views)
Background and Objectives: Statins, which are primarily used for controlling blood cholesterol levels, have a well-known role in inhibiting the inflammatory process and reducing mortality rate of infectious diseases. This study aims to evaluate the effect of atorvastatin along with standard treatment protocol in hospitalized adults with COVID-19.
Methods: This randomized controlled clinical trial was conducted on adults hospitalized due to COVID-19 infection at Shahid Beheshti Hospital in Qom, Iran from April to September 2020. They were randomly divided into groups of treatment (n=37, receiving atorvastatin 40 mg daily for 30 days plus standard treatment protocol) and control (n=37, receiving standard treatment protocol alone). The data were analyzed in SPSS v.22 software using chi-square, paired t-test, and ANOVA. P<0.05 was statistically significant.
Results: The CRP level in the atorvastatin-treated group decreased significantly such that there was a significant difference between the two groups after 30 days (P=0.01). There was no significant difference in Spo2 level on the discharge day. The length of hospitalization in the atorvastatin-treated group was significantly reduced compared to the control group (P<0.05).
Conclusion: The use of atorvastatin as an adjunctive treatment method, can significantly reduce the length of hospitalization and CRP level after 30 days in hospitalized patients.
Methods: This randomized controlled clinical trial was conducted on adults hospitalized due to COVID-19 infection at Shahid Beheshti Hospital in Qom, Iran from April to September 2020. They were randomly divided into groups of treatment (n=37, receiving atorvastatin 40 mg daily for 30 days plus standard treatment protocol) and control (n=37, receiving standard treatment protocol alone). The data were analyzed in SPSS v.22 software using chi-square, paired t-test, and ANOVA. P<0.05 was statistically significant.
Results: The CRP level in the atorvastatin-treated group decreased significantly such that there was a significant difference between the two groups after 30 days (P=0.01). There was no significant difference in Spo2 level on the discharge day. The length of hospitalization in the atorvastatin-treated group was significantly reduced compared to the control group (P<0.05).
Conclusion: The use of atorvastatin as an adjunctive treatment method, can significantly reduce the length of hospitalization and CRP level after 30 days in hospitalized patients.
Type of Study: Original Article |
Subject:
داخلی
Received: 2022/09/26 | Accepted: 2022/11/6 | Published: 2022/11/1
Received: 2022/09/26 | Accepted: 2022/11/6 | Published: 2022/11/1
References
1. Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. 2020; 61(3):E304-12. [DOI:10.15167/2421-4248/jpmh2020.61.3.1530] [DOI:10.18502/ijph.v49i7.3574]
2. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020; 81(2):e16-25. [DOI:10.1016/j.jinf.2020.04.021] [PMID] [PMCID] [DOI:10.1016/j.jinf.2020.04.021]
3. Kow CS, Hasan SS. Meta-analysis of effect of statins in patients with COVID-19. Am J Cardiol. 2020; 134:153-55. [DOI:10.1016/j.amjcard.2020.08.004] [PMID] [PMCID] [DOI:10.1016/j.amjcard.2020.08.004]
4. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: A prospective observational study from the ZOE COVID Study. Lancet. 2022; 399(10335):1618-24. [DOI:10.1016/S0140-6736(22)00327-0] [PMID] [DOI:10.1016/S0140-6736(22)00327-0]
5. Hu B, Huang S, Yin L. The cytokine storm and COVID‐19. J Med Virol. 2021; 93(1):250-6. [DOI:10.1002/jmv.26232] [PMID] [PMCID] [DOI:10.1002/jmv.26232]
6. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020; 11:1708. [DOI:10.3389/fimmu.2020.01708] [PMID] [PMCID] [DOI:10.3389/fimmu.2020.01708]
7. Pawlos A, Niedzielski M, Gorzelak-Pabiś P, Broncel M, Woźniak E. COVID-19: Direct and indirect mechanisms of statins. Int J Mol Sci. 2021; 22(8):4177. [DOI:10.3390/ijms22084177] [PMID] [PMCID] [DOI:10.3390/ijms22084177]
8. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res. 2013; 99(3):417-35. [DOI:10.1016/j.antiviral.2013.06.018] [PMID] [DOI:10.1016/j.antiviral.2013.06.018]
9. Çalıca Utku A, Budak G, Karabay O, Güçlü E, Okan HD, Vatan A. Main symptoms in patients presenting in the COVID-19 period. Scott Med J. 2020; 65(4):127-32. [DOI:10.1177/0036933020949253] [PMID] [PMCID] [DOI:10.1177/0036933020949253]
10. Jean S-S, Hsueh P-R. Old and re-purposed drugs for the treatment of COVID-19. Expert Rev Anti Infect Ther. 2020; 18(9):843-7. [DOI:10.1080/14787210.2020.1771181] [PMID] [PMCID] [DOI:10.1080/14787210.2020.1771181]
11. Nolan J, Monsieurs K, Bossaert L, Böttiger B, Greif R, Lott C, et al. European Resuscitation Council COVID-19 guidelines executive summary. Resuscitation. 2020; 153:45-55. [doi:10.1016/j.resuscitation.2020.06.001] [DOI:10.1016/j.resuscitation.2020.06.001]
12. De Spiegeleer A, Bronselaer A, Teo JT, Byttebier G, De Tré G, Belmans L, et al. The effects of ARBs, ACEis, and statins on clinical outcomes of COVID-19 infection among nursing home residents. J Am Med Dir Assoc. 2020; 21(7):909-14.e2. [DOI:10.1016/j.jamda.2020.06.018] [PMID] [PMCID] [DOI:10.1016/j.jamda.2020.06.018]
13. Davoodi L, Jafarpour H, Oladi Z, Zakariaei Z, Tabarestani M, Ahmadi BM, et al. Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial. Int J Cardiol Heart Vasc. 2021; 36:100875. [DOI:10.1016/j.ijcha.2021.100875] [PMID] [PMCID] [DOI:10.1016/j.ijcha.2021.100875]
14. Tan WYT, Young BE, Lye DC, Chew DEK, Dalan R. Statin use is associated with lower disease severity in COVID-19 infection. Sci Rep. 2020; 10(1):17458. [DOI:10.1038/s41598-020-74492-0] [PMID] [PMCID] [DOI:10.1038/s41598-020-74492-0]
15. Byttebier G, Belmans L, Alexander M, Saxberg BE, De Spiegeleer B, De Spiegeleer A, et al. Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs. Hum Vaccin Immunother. 2021; 17(9):2841-50. [DOI:10.1080/21645515.2021.1920271] [DOI:10.1080/21645515.2021.1920271]
16. Zhang X-J, Qin J-J, Cheng X, Shen L, Zhao Y-C, Yuan Y, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020; 32(2):176-87.e4. [DOI:10.1016/j.cmet.2020.06.015] [PMID] [PMCID] [DOI:10.1016/j.cmet.2020.06.015]
17. Haji Aghajani M, Moradi O, Azhdari Tehrani H, Amini H, Pourheidar E, Hatami F, et al. Promising effects of atorvastatin on mortality and need for mechanical ventilation in patients with severe COVID-19; A retrospective cohort study. Int J Clin Pract. 2021; 75(9):e14434. [DOI:10.1111/ijcp.14434] [PMID] [PMCID] [DOI:10.1111/ijcp.14434]
18. Bifulco M, Ciccarelli M, Bruzzese D, Dipasquale A, Lania AG, Mazziotti G, et al. The benefit of statins in SARS-CoV-2 patients: further metabolic and prospective clinical studies are needed. Endocrine. 2021; 71(2):270-2. [DOI:10.1007/s12020-020-02550-8] [PMID] [PMCID] [DOI:10.1007/s12020-020-02550-8]
19. Hariyanto TI, Kurniawan A. Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr. 2020; 14(6):1613-5. [DOI:10.1016/j.dsx.2020.08.023] [PMID] [PMCID] [DOI:10.1016/j.dsx.2020.08.023]
20. Daniels LB, Sitapati AM, Zhang J, Zou J, Bui QM, Ren J, et al. Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients. Am J Cardiol. 2020; 136:149-55. [DOI:10.1016/j.amjcard.2020.09.012] [PMID] [PMCID] [DOI:10.1016/j.amjcard.2020.09.012]
21. Klok F, Kruip M, Van der Meer N, Arbous M, Gommers D, Kant K, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191:145-7. [DOI:10.1016/j.thromres.2020.04.013] [PMID] [PMCID] [DOI:10.1016/j.thromres.2020.04.013]
22. Poor HD, Ventetuolo CE, Tolbert T, Chun G, Serrao G, Zeidman A, et al. COVID‐19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. Clin Transl Med. 2020; 10(2):e44. [DOI:10.1002/ctm2.44] [PMID] [PMCID] [DOI:10.1002/ctm2.44]
23. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009; 360(18):1851-61. [DOI:10.1056/NEJMoa0900241] [PMID] [PMCID] [DOI:10.1056/NEJMoa0900241]
24. Biere-Rafi S, Hutten BA, Squizzato A, Ageno W, Souverein PC, de Boer A, et al. Statin treatment and the risk of recurrent pulmonary embolism. Eur Heart J. 2013; 34(24):1800-6. [DOI:10.1093/eurheartj/eht046] [PMID] [DOI:10.1093/eurheartj/eht046]
25. Arslan F, Pasterkamp G, de Kleijn DP. Unraveling pleiotropic effects of statins: bit by bit, a slow case with perspective. Circ Res. 2008; 103(4):334-6. [DOI:10.1161/CIRCRESAHA.108.182220] [PMID] [DOI:10.1161/CIRCRESAHA.108.182220]
26. Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA, Chung CW, Trelles-Garcia VP, Friedman HJ. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: A retrospective cohort study. Crit Care. 2020; 24(1):429. [DOI:10.1186/s13054-020-03154-4] [PMID] [PMCID] [DOI:10.1186/s13054-020-03154-4]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Owned by Qom University of Medical Sciences
Published by Qom University of Medical Sciences Press
eISSN: 2008-1375
pISSN: 1735-7799
Email: journal[at]muq.ac.ir
j.mua.ac[at]gmail.com
